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Dear Editor
Disodium Cromoglycate in Asthma ―
Worth to Be Re-appraised
Miyatake et al. published in the journal1 their inter-
esting results suggesting that disodium cromoglycate
(DSCG) inhalations decrease respiratory infections
in adults with asthma. The design was retrospective,
cross-sectional and questionnaire-based, with supple-
mentary lung function and laboratory data available.
Over 200 patients were changed from inhaled corti-
costeroids (ICS) to the ICS and DSCG combination,
and the patients managed as their own controls. After
DSCG was added to ICS therapy, 56% of the patients
rated that asthma symptoms alleviated and 66% that
respiratory infections lessened.
DSCG was widely used for asthma in children, un-
til ICSs were introduced and appeared to be more ef-
fective. Thereafter, the use of DSCG dramatically de-
creased or even totally ceased in many countries.
In 1992―1993, we treated 92 children aged less
than 24 months and hospitalized for wheezing with
either DSCG, ICS or no maintenance for 4 months2 .
The treatment was randomized, but less children
with eosinophilia were allocated into the DSCG group
than into the two other groups. Both DSCG and ICS
diminished wheezing symptoms, compared with con-
trols with no maintenance, but only as long as the
treatment continued. Eight months later, no differ-
ence was seen anymore2 . In 1999 the children were
re-examined at the age of 6―7 years, and we found an
unexpected result: the children treated in infancy by
DSCG had significantly less asthma ( 21% ) than
those with no treatment in infancy (54%) (OR 0.23;
95% CI 0.07―0.77). The figure for those treated with
ICS in infancy was 46%, close to controls3 . The result
was robust in multivariate analyses adjusted for age
and respiratory syncytial virus infection on admis-
sion, atopy and wheezing history in infancy and ICS
therapy later. Eosinophil activity in infancy was a sig-
nificant predictor of later wheezing and asthma, and
after adjustment for blood eosinophilia in infancy, the
statistical significance was lost, albeit the risk for
asthma in the DSCG group remained low (OR 0.21;
95% CI 0.04―1.12)3 . Since DSCG suppresses the pro-
duction of IgE4 and the local accumulation of eosino-
phils5 , in line with the study of Miyatake et al.1 , the
less frequent occurrence of eosinophilia in the DSCG
group perhaps did not confound the results. In the-
ory, the benefits of DSCG might even have been
more pronounced in patients with systemic eosino-
philia. In 2004, when the children were 13―15 years of
age, there were no significant differences between
the infantile treatment groups anymore, which is un-
derstandable in long-term studies with many disease
modifying factors encountered during the follow-up
years.
The advancement in clinical virology has made pos-
sible to find triggering virus in more wheezing or
asthma episodes than earlier. The great majority of
wheezing episodes and exacerbations of asthma in
young children, if not all, are induced by viruses.
Therefore, the results of Miyatake et al. linking
DSCG particularly with less respiratory infections are
promising1 , and call for re-appraisal of the role of
DSCG and other cromones in both children and
adults with asthma or wheezing.
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